All patients should undergo molecular sequencing of their tumors for actionable targets such as mutations in ALK or NTRK, which influences available treatment optionshere is a report with crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer with ALK mutation, resulted in complete response [8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.